Skip to Content

Katy Rezvani, MD, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Translational Research, Department of Stem Cell Transplantation - Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Clinical Medical Director, Department of Stem Cell Transplantation, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2005 Imperial College, London, England, PHD, Transplant Immunology
1993 University College, London, England, MBBS, (with distinction), Medicine
1990 University College, London, England, BSC, (with honors), Neuroanatomy/Neuroscience

Postgraduate Training

2/2001-12/2007 Research Fellowship, LRF/NHLBI funded in Stem Cell Allotransplantation Section (SCAT),, Hematology Branch NHLBI, NIH,, Bethesda, MD
12/1999-2/2001 Clinical Fellowship, Hem-Oncology and Bone Marrow Transplant, Hammersmith Hospital, London, United Kingdom
8/1996-12/1999 Clinical Fellowship, Hammersmith Hospital, London, United Kingdom
2/1996-8/1996 Senior House Officer, University College London Hospital, London, United Kingdom
8/1995-2/1996 Clinical Residency, Royal Marsden Hospital, London, United Kingdom
2/1994-8/1995 Clinical Residency, Harefield and Hillingdon Hospitals, Hillingdon, United Kingdom
2/1994-8/1994 Internship, Mount Vernon Hospital, Northwood, United Kingdom
8/1993-2/1994 Internship, University College London Hospital, London, United Kingdom

Board Certifications

4/2012 Royal College of Physicians, London, England, Fellowship of the Royal College of Physicians (FRCP)
10/2010 Royal College of Pathologists, Fellowship of the Royal College of Pathologists (FRCPath)
2000 Membership of the Royal College of Pathologists (MRCPath), England, Boards in Hematology
1996 Membership of the Royal College of Physicians (MRCP) England, Boards in Internal Medicine


Academic Appointments

Associate Professor, Hematology, and Consultant, Hammersmith Hospital, Imperial College, London, United Kingdom, 8/2011-5/2012
Assistant Professor, Hematology, Clinical Senior Lecturer and Consultant, Hammersmith Hospital, London, England, London, United Kingdom, 1/2008-7/2011

Administrative Appointments/Responsibilities

Clinical Director of the John Goldman Cellular Therapy Laboratory and Clinical Lead Adult Stem Cell Transplant Program, Hammersmith Hospital, London, England, 1/2008-5/2012

Honors and Awards

2011 Clinical Excellence Award (level 6), Hammersmith Hospital, London, England
2010 Clinical Excellence Award (level 3), Hammersmith Hospital, London, England
2007 Best scientific abstract award, American Society of Blood and Marrow Transplantation
2007 Young Investigator Travel Award for best abstract, International Society of Cellular Therapy
2006 Lenfant Biomedical Fellowship Award, National Heart Lung Blood Institute
1993 Distinction in Medicine, University College, London, England
1993 Distinction in Pharmacology, University College, London, England
1993 Distinction in Surgery, University College, London, England
1990 Intercalated BSc Scholarship, Medical Research Council of UK

Selected Publications

Peer-Reviewed Original Research Articles

1. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. e-Pub 9/2015. PMID: 26343946.
2. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. BETTER ALLELE-LEVEL MATCHING IMPROVES TRANSPLANT RELATED MORTALITY AFTER DOUBLE CORD BLOOD TRANSPLANTATION. Haematologica. e-Pub 8/2015. PMID: 26250579.
3. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 5/2015. e-Pub 3/2015. PMCID: PMC4424412.
4. Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJ. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood 125(9):1502-6, 2/2015. e-Pub 11/2014. PMCID: PMC4342362.
5. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Mehta RS, Chemaly R, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution Following Double Cord Blood Transplantation. Biol Blood Marrow Transplant. e-Pub 2/2015. PMID: 25708219.
6. Bigley AB, Rezvani K, Pistillo M, Reed J, Agha N, Kunz H, O'Connor DP, Sekine T, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: Impact of latent cytomegalovirus infection and catecholamine sensitivity. Brain Behav Immun. e-Pub 1/2015. PMID: 25578514.
7. Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, Melenhorst JJ, Larochelle A. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res 14(1):95-104, 1/2015. e-Pub 12/2014. PMID: 25535865.
8. Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K. Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front Immunol 6:36, 2015. e-Pub 2/2015. PMID: 25699052.
9. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Transl Med. e-Pub 11/2014. PMID: 25378655.
10. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-Atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplant Outcomes for AML/MDS Patients with Haploidentical versus 10/10 HLA Matched Unrelated and Related Donors. Biol Blood Marrow Transplant. e-Pub 9/24/2014. PMID: 25263628.
11. Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk 14 Suppl:S18-22, 9/2014. PMID: 25486950.
12. Bigley AB, Rezvani K, Chew C, Sekine T, Pistillo M, Crucian B, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav Immun 39:160-71, 7/2014. e-Pub 11/2013. PMID: 24200514.
13. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B-Cells Are Enriched Within the IgM Memory and Transitional Subsets in Healthy Donors but Deficient In Chronic Graft-Versus-Host Disease. Blood. e-Pub 7/2014. PMID: 25051962.
14. Davies JO, Stringaris K, Barrett JA, Rezvani K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy. e-Pub 5/2014. PMID: 24856895.
15. Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. Br J Haematol 164(4):608-10, 2/2014. e-Pub 11/2013. PMID: 24219400.
16. Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy. e-Pub 2/2014. PMID: 24582458.
17. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2/2014. e-Pub 10/2013. PMID: 24169268.
18. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 16(1):84-9, 1/2014. e-Pub 10/2013. PMCID: PMC3883688.
19. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K. Leukemia-induced phenotypic and functional defects in natural killercells predict failure to achieve remission in acute myeloid leukemia. Haematologica. e-Pub 1/2014. PMID: 24488563.
20. Rezvani K, Barrett J. STAT3: the "Achilles" heel for AML? Blood 123(1):1-2, 1/2014. PMCID: PMC3879899.
21. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16(1):90-100, 1/2014. e-Pub 10/2013. PMID: 24480547.
22. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. e-Pub 12/2013. PMID: 24502832.
23. Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, Macdonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant 48(10):1324-8, 10/2013. e-Pub 5/2013. PMID: 23686098.
24. de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K. Tyrosine Kinase inhibitors impair B cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 122(2):227-38, 7/2013. e-Pub 5/2013. PMID: 23719297.
25. Zou J, Rezvani K, Wang H, Lee KS, Zhang D. BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress. Cell Cycle 12(14). e-Pub 6/2013. PMID: 23797585.
26. Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. e-Pub 2/2013. PMID: 23380743.
27. Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J. Cancer Vaccines and T Cell Therapy. Biol Blood Marrow Transplant 19(1 Suppl), 1/2013. e-Pub 10/2012. PMID: 23041602.
28. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8(10):e76781, 2013. e-Pub 10/2013. PMCID: PMC3800010.
29. Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood 120(3):697-8, 7/2012. PMID: 22822001.
30. Rezvani K, Yong AS, Mielke S, Savani BN, Jafarpour B, Eniafe R, Le RQ, Musse L, Boss C, Childs R, John Barrett A. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother 61(7):1125-36, 7/2012. e-Pub 12/2011. PMID: 22198310.
31. Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 119(21):5030-6, 5/2012. e-Pub 2/2012. PMID: 22371885.
32. Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A. Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol 157(1):125-7, 4/2012. e-Pub 11/2011. PMID: 22050411.
33. Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L. BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol 87(3):298-304, 3/2012. e-Pub 1/2012. PMID: 22231203.
34. Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo R. EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant 18(2):235-40, 2/2012. e-Pub 6/2011. PMID: 21723225.
35. Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 26(2):296-302, 2/2012. e-Pub 8/2011. PMID: 21844874.
36. Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 119(8):1838-43, 2/2012. e-Pub 12/2011. PMID: 22174159.
37. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232-8, 1/2012. e-Pub 11/2011. PMID: 22067393.
38. Mielke S, McIver ZA, Shenoy A, Fellowes V, Khuu H, Stroncek DF, Leitman SF, Childs R, Battiwalla M, Koklanaris E, Haggerty J, Savani BN, Rezvani K, Barrett AJ. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant 17(12):1855-61, 12/2011. e-Pub 5/2011. PMCID: PMC3179818.
39. Rezvani K. CD40-ligand/interleukin-2 vaccines in chronic lymphocytic leukemia: the impact of vaccine design. Cytotherapy 13(9):1029-30, 10/2011. PMID: 21916777.
40. Rezvani K, de Lavallade H. Vaccination strategies in lymphomas and leukaemias: recent progress. Drugs 71(13):1659-74, 9/2011. PMID: 21902290.
41. Rezvani K, de Lavallade H. Improving outcomes in myeloid leukemia patients: does a new DNA vaccine hold the answer? Expert Rev Vaccines 10(7):933-5, 7/2011. PMID: 21806391.
42. Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K. Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant 17(5):632-9, 5/2011. e-Pub 8/11/2010. PMID: 20708085.
43. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 17(5):591-7, 5/2011. e-Pub 8/21/2010. PMCID: PMC3763478.
44. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733-6, 4/7/2011. e-Pub 2/23/2011. PMID: 21346253.
45. Yong AS, Stephens N, Weber G, Li Y, Savani BN, Eniafe R, Keyvanfar K, Kurlander R, Rezvani K, Barrett AJ. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 25(4):629-37, 4/2011. e-Pub 1/2011. PMCID: PMC3076540.
46. Gerrard G, Mudge K, Stewart R, Foskett P, Stevens D, Khorashad JS, Szydlo R, Rezvani K, Marin D, Reid A, Apperley J, Goldman J, Foroni L. Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies. Am J Hematol 86(3):313-5, 3/2011. e-Pub 2/2011. PMID: 21328433.
47. Rezvani K. Peptide vaccine therapy for leukemia. Int J Hematol 93(3):274-80, 3/2011. e-Pub 3/2011. PMID: 21380929.
48. Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, Barrett AJ. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 96(3):432-40, 3/2011. e-Pub 12/2010. PMCID: PMC3046275.
49. de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 96(2):307-14, 2/2011. e-Pub 10/2010. PMCID: PMC3031700.
50. Rezvani K. Posttransplantation vaccination: concepts today and on the horizon. Hematology Am Soc Hematol Educ Program 2011:299-304, 2011. PMID: 22160049.
51. Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Foroni L, Reid A, de Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 116(25):5497-500, 12/2010. e-Pub 9/2010. PMID: 20833982.
52. Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood 116(12):2033-9, 9/2010. e-Pub 6/2010. PMID: 20562327.
53. Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116(6):1014-6, 8/2010. PMCID: PMC2924222.
54. Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24(6):1243-5, 6/2010. e-Pub 5/2010. PMID: 20445576.
55. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381-8, 5/2010. e-Pub 4/2010. PMID: 20385986.
56. Pavlu J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 115(20):4018-20, 5/2010. e-Pub 3/2010. PMID: 20304808.
57. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95(2):224-31, 2/2010. e-Pub 10/2009. PMCID: PMC2817024.
58. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 44(12):769-77, 12/2009. e-Pub 10/2009. PMID: 19855439.
59. Barrett J, Rezvani K. Immunotherapy: Can we include vaccines with stem-cell transplantation? Nat Rev Clin Oncol 6(9):503-5, 9/2009. PMID: 19707241.
60. Khorashad JS, Wagner S, Greener L, Marin D, Reid A, Milojkovic D, Patel H, Willimott S, Rezvani K, Gerrard G, Loaiza S, Davis J, Goldman J, Melo J, Apperley J, Foroni L. The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. Haematologica 94(6):861-4, 6/2009. e-Pub 4/2009. PMCID: PMC2688579.
61. Rezvani K, Teng Y, Pan Y, Dani JA, Lindstrom J, García Gras EA, McIntosh JM, De Biasi M. UBXD4, a UBX-containing protein, regulates the cell surface number and stability of alpha3-containing nicotinic acetylcholine receptors. J Neurosci 29(21):6883-96, 5/2009. PMCID: PMC2935801.
62. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10):2245-55, 3/2009. e-Pub 11/2008. PMCID: PMC2652370.
63. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol 21(3):437-53, 9/2008. PMCID: PMC3757471.
64. Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22(9):1721-7, 9/2008. e-Pub 6/2008. PMCID: PMC2574650.
65. Rezvani K. PR1 vaccination in myeloid malignancies. Expert Rev Vaccines 7(7):867-75, 9/2008. PMID: 18767937.
66. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, Fan Y, Gostick E, Price DA, Scotto C, Read EJ, Barrett AJ. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111(8):4392-402, 4/2008. e-Pub 9/2007. PMCID: PMC2288732.
67. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111(1):236-42, 1/2008. e-Pub 9/2007. PMCID: PMC2200809.
68. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 45(1):39-48, 1/2008. PMID: 18179968.
69. Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L, Superata J, Kurlander R, Singh A, Childs R, Barrett AJ. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 13(10):1216-23, 10/2007. e-Pub 8/2007. PMCID: PMC3426353.
70. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, Zeilah J, Kurlander R, Srinivasan R, Childs R, Hensel N, Barrett AJ. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 21(10):2145-52, 10/2007. e-Pub 8/2007. PMID: 17673900.
71. Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 110(5):1603-6, 9/2007. e-Pub 4/2007. PMCID: PMC1975843.
72. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 110(6):1924-32, 9/2007. e-Pub 5/2007. PMCID: PMC1976363.
73. Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, Vitetta ES, Barrett AJ. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 110(5):1689-97, 9/2007. e-Pub 5/2007. PMCID: PMC1975850.
74. Yong AS, Rezvani K, Savani BN, Eniafe R, Mielke S, Goldman JM, Barrett AJ. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 110(2):770-5, 7/2007. e-Pub 4/2007. PMCID: PMC1924474.
75. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol 148(2):189-98, 5/2007. PMCID: PMC1868869.
76. Grube M, Moritz S, Obermann EC, Rezvani K, Mackensen A, Andreesen R, Holler E. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 13(3):1053-60, 2/2007. PMID: 17289902.
77. Rezvani K, Price DA, Brenchley JM, Kilical Y, Gostick E, Sconocchia G, Hansmann K, Kurlander R, Douek DC, Barrett AJ. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy 9(3):245-51, 2007. PMID: 17464756.
78. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, Rezvani K, Karimpour S, Childs R, Barrett AJ. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 12(12):1261-9, 12/2006. PMCID: PMC1849949.
79. Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 12(12):1318-25, 12/2006. PMID: 17162214.
80. Li J, Melenhorst J, Hensel N, Rezvani K, Sconocchia G, Kilical Y, Hou J, Curfman B, Major E, Barrett AJ. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol 87(Pt 10):2951-60, 10/2006. PMID: 16963754.
81. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108(4):1291-7, 8/2006. e-Pub 4/2006. PMCID: PMC1895877.
82. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, Leitman S, Read EJ, Childs R, Barrett AJ. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107(4):1688-95, 2/2006. e-Pub 8/2005. PMCID: PMC1895415.
83. Barrett J, Rezvani K. Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr Opin Hematol 13(1):15-20, 1/2006. PMID: 16319682.
84. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, Barrett AJ. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 11(24 Pt 1):8799-807, 12/2005. PMID: 16361568.
85. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D, Apperley JF. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 75(5):376-83, 11/2005. PMID: 16191086.
86. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett AJ. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 106(10):3666-72, 11/2005. e-Pub 7/2005. PMCID: PMC1895055.
87. Savani BN, Srinivasan R, Espinoza-Delgado I, Dorrance C, Takahashi Y, Igarashi T, Rezvani K, Lundqvist A, Barrett AJ, Childs RW. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol 6(10):809-12, 10/2005. PMID: 16198987.
88. Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, Rezvani K, Price DA, Hensel NF, Douek DC, Barrett AJ. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res 11(12):4495-503, 6/2005. PMCID: PMC2366103.
89. Sconocchia G, Provenzano M, Rezvani K, Li J, Melenhorst J, Hensel N, Barrett AJ. CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines. J Transl Med 3(1):15, 4/14/2005. e-Pub 4/14/2005. PMCID: PMC1087889.
90. Sconocchia G, Keyvanfar K, El Ouriaghli F, Grube M, Rezvani K, Fujiwara H, McCoy JP, Hensel N, Barrett AJ. Phenotype and function of a CD56+ peripheral blood monocyte. Leukemia 19(1):69-76, 1/2005. PMID: 15526027.
91. Sconocchia G, Fujiwara H, Rezvani K, Keyvanfar K, El Ouriaghli F, Grube M, Melenhorst J, Hensel N, Barrett AJ. G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. J Leukoc Biol 76(6):1214-9, 12/2004. e-Pub 9/2/2004. PMID: 15345723.
92. Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, Sconocchia G, Melenhorst J, Hensel N, Douek DC, Barrett AJ. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood 103(8):3076-83, 4/2004. e-Pub 12/2003. PMID: 15070688.
93. Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Clin Cancer Res 10(3):1047-56, 2/2004. PMID: 14871984.
94. El-Ouriaghli F, Sloand E, Mainwaring L, Fujiwara H, Keyvanfar K, Melenhorst JJ, Rezvani K, Sconocchia G, Solomon S, Hensel N, Barrett AJ. Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Blood 102(10):3786-92, 11/2003. e-Pub 7/2003. PMID: 12893759.
95. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, Hensel N, Douek DC, Barrett AJ. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102(8):2892-900, 10/2003. e-Pub 6/2003. PMID: 12829610.
96. Rezvani K, Mee M, Dawson S, McIlhinney J, Fujita J, Mayer RJ. Proteasomal interactors control activities as diverse as the cell cycle and glutaminergic neurotransmission. Biochem Soc Trans 31(2):470-3, 4/2003. PMID: 12653665.
97. Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program:350-71, 2003. PMID: 14633790.
98. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, Rezvani K, Craddock C, Rassam S, Prentice HG. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol 115(3):622-9, 12/2001. PMID: 11736947.
99. Pocock CF, Lucas GF, Giles C, Vassiliou G, Cwynarski K, Rezvani K, Apperley JF, Goldman JM. Immune neutropenia associated with anti-human neutrophil antigen-2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor. Br J Haematol 113(2):483-5, 5/2001. PMID: 11380420.
100. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NC, Goldman JM. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97(6):1560-5, 3/2001. PMID: 11238091.
101. Rezvani K, Flanagan AM, Sarma U, Constantinovici N, Bain BJ. Investigation of ethnic neutropenia by assessment of bone marrow colony-forming cells. Acta Haematol 105(1):32-7, 2001. PMID: 11340251.
102. Pocock C, Szydlo R, Davis J, de La Fuente J, Craddock C, Cwynarski K, Olavarria E, Rezvani K, Kanfer E, Apperley J, Goldman J. Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. Hematol J 2(4):265-72, 2001. PMID: 11920259.
103. Phillips D, Rezvani K, Bain BJ. Exercise induced mobilisation of the marginated granulocyte pool in the investigation of ethnic neutropenia. J Clin Pathol 53(6):481-3, 6/2000. PMCID: PMC1731218.
Other Articles
1. Rezvani K. Aurora: a new direction for a new dawn. Blood 119(2):322-3, 1/2012. PMID: 22247517.
2. Rezvani K. MAGE: the spell is broken. Clin Cancer Res 17(22):6955-7, 11/2011. e-Pub 11/2011. PMID: 22068655.


1. Parmar S, Liu X, Yvon E, Zweidler-mcCay P, Shah N, Rezvani K, McNiece I, Shpall E. Ex vivo Fucosylation Enhances Regulatory T Cell Anti-Graft Versus Host Disease Potency in Mice. American Society of Hematology, 12/2014.
2. Ahmed S, Shpall E, Gulbis A, Jones R, Martinez C, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat U, Alousi A, Nieto Y, Hosing C, Bashir Q, Kebriaei P, Qazilbash M, Champlin R, Mulanovich V. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. American Society of Hematology, 12/2014.
3. Oran B, Cao K, Saliba R, Hosing C, Popat U, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin R, Rezvani K, Shpall E. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. American Society of Hematology, 12/2014.
4. Shashank S Ghantoji, Sumana Goddu, Swapna Sreenivasula, Dimpy P Shah, Betul Oran, Katy Rezvani, Gabriela Rondon, Elizabeth J. Shpall, Roy F Chemaly. Characteristics and Outcome of Cytomegalovirus (CMV) Infections in 95 Cord Blood Transplant (CBT) Recipients: The MD Anderson Experience. Bio Blood Marrrow Transplant, 2014.
5. Sai Ravi Pingali, Denai Milton, Antonio di Stasi, Rushang D Patel, Partow Kebriaei, Uday R. Popat, Amin M. Alousi, Paolo Anderlini, Muzaffar H. Qazilbash, Chitra Hosing, Katy Rezvani, Qaiser Bashir, Betul Oran, Elizabeth J. Shpall, Issa F. Khouri, Richard E. Champlin, Stefan O. Ciurea. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Bio Blood Marrow Transplant, 2014.
6. Anushruti Sarvaria, Ahmad Khoder, Abdullah Alsuliman, Claude Chew, Takuya Sekine, Nichola Cooper, Hugues de Lavallade, Muharrem Muftuoglu, Eric Yvon, Amir Hamdi, Amin M. Alousi, Lisa St. John, David Marin, Kate Stringaris, Enli Liu, Jeffrey Molldrem, Nina Shah, Simrit Parmar, Ian McNiece, Richard E. Champlin, Elizabeth J. Shpall, Katy Rezvani. Immunoregulatory B Cells Are Enriched within Transitional and IgM Memory B Cell Subsets in Healthy Donors but Are Reduced and Functionally Impaired in Patients with Chronic Graft-Versus-Host Disease. Bio Blood Marrrow Transplant, 2014.
7. Amer Najjar, PhD, Simon N Robinson, PhD, Claude Chew, Li Sufang, Eric Yvon, PhD, Michael W Thomas, PhD, Katy Rezvani, MD, PhD, Elizabeth J. Shpall, MD, PhD and Nina Shah, MD. NK Cells Kill Myeloma Cells By Increasing ER Stress and Decreasing Autophagy Levels. NKG2D and NKP30 Are Involved In These Processes. American Society of Hematology, 2013.
8. Pratap Neelakantan, MRCP1*, Gareth Gerrard, PhD1*, Letizia Foroni1, Dragana Milojkovic1*, Jane Apperley1, Richard Szydlo, PhD2*, Marco Bua1*, Alistair G Reid, BSc, PhD1*, Katy Rezvani, MBBS, PhD, MRCP, FRCPath1, John M Goldman, MD1 and David Marin1. Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?. ASH Annual Meeting 2012 Abstracts, 12/2012.
9. ate Stringaris, MD, MRCP, FRCPath1*, Takuye Sekine2*, Ahmad Khoder, M.D.3*, Abdullah Alsuliman3*, Pavlu Jiri4*, Anushruthi Sarvaria4*, David Marin5, Jane Apperley6, A. John Barrett, MD7 and Katayoun Rezvani, M.D., PhD8. Defective Natural Killer (NK) Receptor Expression and Effector Function in Acute Myeloid Leukemia Partially Normalize At Remission and Predict Response to Chemotherapy. ASH Annual Meeting 2012 Abstracts, 12/2012.
10. Pratap Neelakantan, MRCP*, Dragana Milojkovic*, Gareth Gerrard, PhD*, Letizia Foroni, Jane Apperley, Richard M Szydlo*, Alistair Reid, PhD*, Marco Bua*, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD and David Marin. Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?. ASH Annual Meeting 2012 Abstracts, 12/2012.

Book Chapters

1. Neelakantan P and Rezvani K. : Peptide Vaccines in Myeloid Leukemias. In: Handbook of the Biologically Active Peptides, The 2nd Edition. In Press.
2. Alsuliman A, Garland P, and Rezvani K. The Role of Regulatory T Cells in GVL and GVHD. Nova Science Publishers. In Press.
3. Wickramasinghe SN, Rezvani K. ISCH- The Measurement of Serum Vitamin B 12, Serum Folate and Red Cell Folate. In: Advanced Laboratory Methods in Haematology, 2002.

Grant & Contract Support

Title: Mesenchymal Stem Cells for Adriamycin Induced Cardiotoxicity
Funding Source: UTMDACC
Role: Co-Investigator
Principal Investigator: Olson
Duration: 10/1/2015 - 9/30/2018
Title: A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Parmar
Duration: 4/1/2015 - 3/31/2018
Title: Curative Cellular Therapy for CLL Using Off-the-Shelf Cord Blood Derived Natural Killer Cells
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2014 - 9/30/2017
Title: MDS/AML Moonshot Cell Therapy Project
Funding Source: UTMDACC
Role: Co-Investigator
Duration: 9/1/2014 - 8/31/2016
Title: CMV Adoptive T cell Therapy for GBM patients
Funding Source: The GBM Moonshot
Role: Principal Investigator
Duration: 9/1/2014 - 8/31/2016
Title: CMV Adoptive T cell Therapy for GBM patients
Funding Source: The Rose Foundation
Role: Principal Investigator
Duration: 9/1/2014 - 8/31/2016
Title: Curative cell-based therapies for chronic lymphocytic leukemia (CLL)
Funding Source: Sister Institution Network Fund Grant (SINF)
Role: Principal Investigator
Duration: 2/1/2014 - 1/31/2016
Title: Clinical application of genetically engineered cord blood derived natural killer cells.
Funding Source: Mike Hogg Foundation
Role: Principal Investigator
Duration: 2/1/2014 - 1/3/2015
Title: Moon Shot Ibrutinib Flagship
Funding Source: CLL Global Research Foundation
Role: Co-Investigator
Principal Investigator: McNiece,Shpall
Duration: 9/1/2013 - 8/31/2014
Title: Application of natural killer (NK) adoptive immmunotherapy to overcome immunological abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/20/2012 - 4/30/2014
Title: “A Randomized Phase II Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination with Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease (GVHD)”
Funding Source: Therakos
Role: Co-Principal Investigator
Principal Investigator: Alousi
Duration: 10/8/2009 - 10/31/2015
Title: Immunotherapy in chronic myeloid leukemia
Funding Source: Marie Curie Reintegration Fellowship
Role: Principal Investigator
Duration: 2/2009 - 1/2011
Title: Development of immunotherapeutic strategies to overcome tolerance in leukemia
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 4/2008 - 3/2010
Title: Activation & Expansion of CLL specific T-cells to study the immune reconstitution following Infusion of CD3/CD28 bead- activated and expaned T cells in patients with chronic lymphocytic leukemia following alemtuzumab based therapy
Funding Source: CLL Foundation
Role: Co-Investigator
Principal Investigator: Hosing
Duration: 2/26/2008 - 5/31/2014
Title: Higher Education Funding Council for England
Funding Source: NHS Clinical Senior lectureship (HEFCE-NHS-CLS)
Role: Award
Duration: 2008 - 2013
Title: The Therapy of CML, Project 2
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Richard E Champlin, MD
Duration: 2/12/1997 - 6/30/2016

Last updated: 6/17/2015